anonymous
Guest
anonymous
Guest
Something for the BMS BOD and current executive (ahem...) 'Brain Trust to consider;
This rash of commercial acquisitions so far, (including the overarching Celgene debacle), have only benefitted the acquired company, and the 'Dealmakers' themselves.
At some point, the BOD and institutional bagholders will ream these dunces.
This rash of commercial acquisitions so far, (including the overarching Celgene debacle), have only benefitted the acquired company, and the 'Dealmakers' themselves.
At some point, the BOD and institutional bagholders will ream these dunces.